265 related articles for article (PubMed ID: 35570542)
1. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
2. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
5. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
6. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Park SH; Binder G; Corman S; Botteman M
J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
[No Abstract] [Full Text] [Related]
7. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
8. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
11. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
Clark-Snow RA; Vidall C; Börjeson S; Jahn P
Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
13. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
14. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
15. NEPA as antiemetic prophylaxis after failure of 5HT
Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
[TBL] [Abstract][Full Text] [Related]
16. Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Md Yusof M; Abdullah MM; Yap BK; Ng SC; Low JSH; Lam KS; Ahmad Badruddin RBA; Lai CNB; Lau KL; Chong KJ; Nonis JG; Ahmad Annuar MA; Abdul Rahman MHFB
Asia Pac J Clin Oncol; 2022 Aug; 18(4):419-427. PubMed ID: 34811924
[TBL] [Abstract][Full Text] [Related]
17. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M
Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
